Lutonix, Inc.

Lutonix, Inc. is a leader in the biotechnology and healthcare industries, with a focus on delivering precision and safety in every inflation for optimal arterial health. The company's flagship product, Lutonix DCB, is an innovative drug-coated balloon catheter that administers paclitaxel directly to the arterial wall with a brief inflation. This unique technology aims to avert arterial restenosis by efficiently delivering an effective therapeutic dose to the artery wall while maintaining a minimal drug load on the balloon, thereby limiting systemic exposure to paclitaxel and optimizing safety. Founded in 2007 and headquartered in the United States, Lutonix, Inc. received a significant $10.00M Series C investment on 13th December 2010, demonstrating confidence in its groundbreaking approach to arterial health.